The safety and efficacy of using high dose intravenous epoetin beta (100,000IU) for treating human acute stroke (within 8 hours) have been confirmed [Ehrenreich 2002]. The therapeutic margin of EPO is very wide. Even at very high serum levels no adverse effects have been observed [NeoRecormon information sheet, Roche].